SG001
1 product
2 abstracts
Abstract
Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study.Org: CSPC zhongqi pharmaceutical technology Co. Ltd.,
Abstract
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.Org: Zhejiang Chinese Medical University,
Product
SG001